Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial
暂无分享,去创建一个
A. Skene | E. Braunwald | C. Cannon | A. Charlesworth | C. McCabe | B. Scirica | R. Aster | J. Brassard | Richard Cooper | C. Mccabe
[1] M. J. Tafreshi,et al. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. , 2006, The American journal of cardiology.
[2] E. Topol,et al. Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association With Clinical Outcome in Patients Undergoing Coronary Stenting , 2004, Circulation.
[3] R. Wynn,et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia. , 2003, Blood.
[4] C. Cannon,et al. Acute Thrombocytopenia in Patients Treated with the Oral Glycoprotein IIb/IIIa Inhibitors Xemilofiban and Orbofiban: Evidence for an Immune Etiology , 2002, Thrombosis and Haemostasis.
[5] R. Aster,et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. , 2002, Blood.
[6] R. Wynn,et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. , 2002, Blood.
[7] C. Bode,et al. Intrinsic activating properties of GP IIb/IIIa blockers. , 2001, Thrombosis research.
[8] Second Symphony Investigators. Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes , 2001, Circulation.
[9] Deepak L. Bhatt,et al. Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists: A Meta-Analysis of Phase III Multicenter Randomized Trials , 2001, Circulation.
[10] P. Théroux,et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. , 2000, Journal of the American College of Cardiology.
[11] A. Skene,et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. , 2000, Circulation.
[12] R. Califf,et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. , 2000, American heart journal.
[13] P Serruys,et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. , 2000, The New England journal of medicine.
[14] C. Cannon,et al. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. , 2000, The American journal of cardiology.
[15] B. Sobel,et al. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. , 2000, Cardiovascular research.
[16] C. Bode,et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. , 1999, The American journal of cardiology.
[17] B E Sobel,et al. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. , 1999, The American journal of cardiology.
[18] R. Califf,et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. , 1999, Circulation.
[19] V. Fuster,et al. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. , 1999, JAMA.
[20] L. Horstman,et al. Platelet microparticles: a wide-angle perspective. , 1999, Critical reviews in oncology/hematology.
[21] P. Jumes,et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. , 1999, Blood.
[22] Y. Matsuzawa,et al. Association Between Ligand-Induced Conformational Changes of Integrin IIbβ3 and IIbβ3-Mediated Intracellular Ca2+ Signaling , 1998 .
[23] C. Bode,et al. Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors , 1998 .
[24] R. Califf,et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. , 1998, Journal of the American College of Cardiology.
[25] R. Giugliano,et al. Thrombocytopenia With GP IIb/IIIa Inhibitors: A Meta-Analysis , 1998 .
[26] Y. Matsuzawa,et al. Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling. , 1998, Blood.
[27] C. Bode,et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. , 1998, Blood.
[28] J. Kelton,et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. , 1994, Blood.
[29] K. Lee,et al. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. , 1994, Journal of the American College of Cardiology.
[30] Xiaoping Du,et al. Ligands “activate” integrin α IIb β 3 (platelet GPIIb-IIIa) , 1991, Cell.
[31] Xiaoping Du,et al. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). , 1991, Cell.